LYMPHIR is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior ...

At the same time, there have been noted barriers to implementation of PROs in the United States, most notably lack of insurance reimbursement. 12 Amid evidence that PRO programs can be cost-effective ...